Sanofi/Regeneron's Libtayo shows benefit in BCC

5th May 2020 Uncategorised 0

BCC marks the second non-melanoma skin cancer for which Libtayo has demonstrated first-in-class data, the firms note

More: Sanofi/Regeneron's Libtayo shows benefit in BCC
Source: News